15 news items
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
by their commitment to patients, their people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK
31 May 24
-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our
ddqjo 6ue4k0afe672ad2ncphsufpx4xm
TAK
16 May 24
, NYSE:TAK), a global, values-based, R&D-driven biopharmaceutical leader headquartered
nf5dccpmwpdoh83etp
ACIU
TAK
13 May 24
of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered
ta898uktcl5pup4wou o14bx6
ACIU
TAK
13 May 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people
oyafqg24d2 n6ma8zg5dq5pgu1ppmx5lo
TAK
9 May 24
Core Operating Profit Change of -13.3% at CER Reflecting Generic Impact and Investment in R&D and Data, Digital & Technology
3b13pmf4k4g47w65h4y5z6l6u27722x73i8z0p8hrrc5
TAK
26 Apr 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people
9p6nv5dizuf5l1
TAK
22 Apr 24
the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven
34rlpexxv
TAK
18 Apr 24
and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
1061ar5ktxt2dajqzgj9vcmc7 88c5t88j6
TAK
27 Mar 24
: 4502) (NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical
jctk3 xho46p0wmn68m8t
TAK
26 Mar 24
values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet
cub27y5oyxy3qxr2ajng6ae9f839ds2y242zunxky5577rpvgmx
TAK
26 Mar 24
option specifically approved to treat this ultra-rare condition," said Yasushi Kajii, Head, R&D Japan Region at Takeda. "Developing innovative
- Prev
- 1
- Next